Heart failure: Not a single organ disease but a multisystem syndrome

British Journal of Hospital Medicine

Volumn 76, Issue 6, 2015, Pages 330-336

  Warriner, David ^a   Sheridan, Paul ^b   Lawford, Patricia ^c  

^a Department of Cardiology Doncaster Royal Infimary ^*  (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE; URIC ACID;

BLOOD; COMPLICATION; ENDOCRINE SYSTEM; HEART FAILURE; HUMAN; IMMUNOLOGY; KIDNEY; METABOLISM; MULTIPLE ORGAN FAILURE; MUSCULOSKELETAL SYSTEM; PATHOPHYSIOLOGY; RESPIRATORY SYSTEM;

ENDOCRINE SYSTEM; HEART FAILURE; HUMANS; KIDNEY; MULTIPLE ORGAN FAILURE; MUSCULOSKELETAL SYSTEM; PARATHYROID HORMONE; RESPIRATORY SYSTEM; URIC ACID;

EID: 84930794672     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2015.76.6.330     Document Type: Conference Paper

References (57)

1. Alonso-Martínez JL, Llorente-Diez B, Echegaray-Agara M, Olaz- Preciado F, Urbieta-Echezarreta M, González-Arencibia C (2002) C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 4: 331-6 (doi: 10.1016/s1388- 9842(02)00021-1).
2. Ameri P, Ronco D, Casu M et al (2010) High prevalence of vitamin D deficiency and its association with left ventricular dilation: An echocardiography study in elderly patients with chronic heart failure. Nutr Metab Cardiovasc Dis 20: 633-40.
3. Amin A, Vakilian F, Maleki M (2011) Serum uric acid levels correlate with filling pressures in systolic heart failure. Congest Heart Fail 17: 79-83 (doi: 10.1111/j.1751-7133.2010.00205.x).
4. Anand IS, Latini R, Florea VG et al (2005) C-reactive protein in heart failure. Circulation 112: 1428-34 (doi: 10.1161/circulationaha.104.508465).
5. Andrews R, Walsh JT, Evans A, Curtis S, Cowley AJ (1997) Abnormalities of skeletal muscle metabolism in patients with chronic heart failure: evidence that they are present at rest. Heart 77: 159-63.
6. Anker SD, Ponikowski P, Varney S et al (1997) Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349: 1050-3 (doi: 10.1016/S0140-6736(96)07015-8).
7. Boerrigter G, Costello-Boerrigter LC, Abraham WT et al (2008) Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail 14: 539-46 (doi: 10.1016/j.cardfail.2008.03.009).
8. Boxer RS, Dauser DA, Walsh SJ, Hager WD, Kenny AM (2008) The association between vitamin D and inflammation with the 6-minute walk and frailty in patients with heart failure. J Am Geriatr Soc 56: 454-61 (doi: 10.1111/j.1532-5415.2007.01601.x).
9. Bradley TD, Floras JS (2003) Sleep apnea and heart failure: part ii: central sleep apnea. Circulation 107: 1822-6 (doi: 10.1161/01. cir.0000061758.05044.64).
10. Clark AL (2006) Origin of symptoms in chronic heart failure. Heart 92: 12-16 (doi: 10.1136/hrt.2005.066886).
11. Coats AJS, Clark AL, Piepoli M, Volterrani M, Poole-Wilson PA (1994) Symptoms and quality of life in heart failure: The muscle hypothesis. Br Heart J 72: S36-S39 (doi: 10.1136/hrt.72.2-Suppl.S36).
12. Cowie MR, Woehrle H, Wegscheider K et al (2013) Rationale and design of the SERVE-HF study: Treatment of sleep-disordered breathing with predominant central sleep apnoea with adaptive servo-ventilation in patients with chronic heart failure. Eur J Heart Fail 15: 937-43 (doi: 10.1093/eurjhf/hft051).
13. Dall'ago P, Chiappa GR, Guths H, Stein R, Ribeiro JP (2006) Inspiratory muscle training in patients with heart failure and inspiratory muscle weakness: A randomized trial. J Am Coll Cardiol 47: 757-63 (doi: 10.1016/j.jacc.2005.09.052).
14. Dickstein K, Cohen-Solal A, Filippatos G et al (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388-442 (doi: 10.1093/eurheartj/ehn309).
15. Doehner W, Schoene N, Rauchhaus M et al (2002) Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure. Circulation 105: 2619-24 (doi: 10.1161/01. cir.0000017502.58595.ed).
16. Emdin M, Passino C, Prontera C et al (2004) Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Me 42: 627-36 (doi: 10.1515/cclm.2004.108).
17. Felker GM, Allen LA, Pocock SJ et al (2007) Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol 50: 40-7 (doi: 10.1016/j.jacc.2007.02.067).
18. Figueiredo EL, Leão FVG, Oliveira LV, Moreira MCV, Figueiredo AFS (2008) Microalbuminuria in nondiabetic and nonhypertensive systolic heart failure patients. Congest Heart Fail 14: 234-8 (doi: 10.1111/j.1751-7133.2008.00008.x).
19. Fischer D, Rossa S, Landmesser U et al (2005) Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 26: 65-9 (doi: 10.1093/eurheartj/ehi001).
20. Francis DP, Shamim W, Davies LC et al (2000) Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO(2)slope and peak VO(2). Eur Heart J 21: 154-61 (doi: 10.1053/euhj.1999.1863).
21. Gary RA, Cress ME, Higgins MK, Smith AL, Dunbar SB (2011) Combined Aerobic and resistance exercise program improves task performance in patients with heart failure. Arch Phys Med Rehabil 92: 1371-81.
22. Gavin AD, Struthers AD (2005) Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 91: 749-53 (doi: 10.1136/hrt.2004.040477).
23. Hagstrom E, Ingelsson E, Sundstrom J et al (2010) Plasma parathyroid hormone and risk of congestive heart failure in the community Eur J Heart Fail 12: 1186-92 (doi: 10.1093/eurjhf/hfq134).
24. Hamilton MA, Stevenson LW, Luu M, Walden JA (1990) Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol 16: 91-5.
25. Hornig B, Maier V, Drexler H (1996) Physical training improves endothelial function in patients with chronic heart failure. Circulation 93: 210-14 (doi: 10.1161/01.cir.93.2.210).
26. Hunt SA, Abraham WT, Chin MH et al (2009) 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119: e391-e479 (doi: 10.1161/CIRCULATIONAHA.109.192065).
27. Jackson CE, Solomon SD, Gerstein HC et al (2009) Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 374: 543-50 (doi: 10.1016/S0140-6736(09)61378-7).
28. Jackson CE, Macdonald MR, Petrie MC et al (2011) Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. Eur J Heart Fail 13: 746-54 (doi: 10.1093/eurjhf/hfr031).
29. Johnson RL (2000) Gas exchange efficiency in congestive heart failure. Circulation 101: 2774-6 (doi: 10.1161/01.cir.101.24.2774).
30. Katz SD, Krum H, Khan T, Knecht M (1996) Exercise-induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: role of endothelium-derived nitric oxide. J Am Coll Cardiol 28: 585-90.
31. Katz SD, Hryniewicz K, Hriljac I et al (2005) Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 111: 310-14 (doi: 10.1161/01. cir.0000153349.77489.cf).
32. Kittleson MM, St John ME, Bead V et al (2007) Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. Heart 93: 365-7 (doi: 10.1136/hrt.2006.090845).
33. Kleber FX, Vietzke G, Wernecke KD et al (2000) Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation 101: 2803-9 (doi: 10.1161/01.cir.101.24.2803).
34. Koga H, Kaku T, Hashiba K (1988) Primary hypothyroidism in severe chronic heart failure. Jpn J Med 27: 42-8.
35. Krack A, Sharma R, Figulla HR, Anker SD (2005) The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 26: 2368-74 (doi: 10.1093/eurheartj/ehi389).
36. Krishnan E (2009) Hyperuricemia and incident heart failure. Circ Heart Fail 2: 556-62 (doi: 10.1161/CIRCHEARTFAILURE.108.797662).
37. Lanfranchi PA, Braghiroli A, Bosimini E et al (1999 Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation 99: 1435-40 (doi: 10.1161/01.cir.99.11.1435).
38. Leyva F, Anker SD, Godsland IF et al (1998) Uric acid in chronic heart failure: A marker of chronic inflammation. Eur Heart J 19: 1814-22 (doi: 10.1053/euhj.1998.1188).
39. Mancini DM, Walter G, Reichek N et al (1992) Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 85: 1364-73.
40. Masson S, Latini R, Milani V et al (2010) Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure. Circ Heart Fail 3: 65-72 (doi: 10.1161/circheartfailure.109.881805).
41. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW (2004) Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109: 1004-9 (doi: 10.1161/01.CIR.0000116764.53225.A9).
42. McMurray JJV, Kjekshus J, Gullestad L et al (2009) Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA). Circulation 120: 2188-96 (doi: 10.1161/circulationaha.109.849117).
43. Mettauer B, Zoll J, Sanchez H et al (2001) Oxidative capacity of skeletal muscle in heart failure patients versus sedentary or active control subjects. J Am Coll Cardiol 38: 947-54.
44. Meyer B, Mortl D, Strecker K et al (2005) Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. J Am Coll Cardiol 46: 1011-18 (doi: 10.1016/j.jacc.2005.04.060).
45. Mozaffarian D, Anker SD, Anand I et al (2007) Prediction of mode of death in heart failure: The Seattle Heart Failure Model. Circulation 116: 392-8 (doi: 10.1161/CIRCULATIONAHA.106.687103).
46. Nagatomo Y, Yoshikawa T, Kohno T et al (2007) Effects of β-blocker therapy on high sensitivity C-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure. J Card Fail 13: 365-71.
47. Nakagomi A, Seino Y, Endoh Y, Kusama Y, Atarashi H, Mizuno K (2010) Upregulation of monocyte proinflammatory cytokine production by C-reactive protein is significantly related to ongoing myocardial damage and future cardiac events in patients with chronic heart failure. J Card Fail 16: 562-71.
48. Pingitore A, Landi P, Taddei MC, Ripoli A, L'abbate A, Iervasi G (2005) Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 118: 132-6 (doi: 10.1016/j. amjmed.2004.07.052).
49. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal Syndrome. J Am Coll Cardiol 52: 1527-39.
50. Sánchez-Lázaro IJ, Almenar L, Reganon E et al (2008) Inflammatory markers in stable heart failure and their relationship with functional class. Int J Cardiol 129: 388-93.
51. Senden PJ, Sabelis LWE, Zonderland ML et al (2004) Determinants of maximal exercise performance in chronic heart failure. Eur J Cardiovasc Prev Rehabil 11: 41-7 (doi: 10.1097/01. hjr.0000116825.84388.eb).
52. Sin DD, Logan AG, Fitzgerald FS, Liu PP, Bradley TD (2000) Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation 102: 61-6 (doi: 10.1161/01.cir.102.1.61).
53. Stockton KA, Mengersen K, Paratz JD, Kandiah D, Bennell KL (2011) Effect of vitamin D supplementation on muscle strength: A systematic review and meta-analysis. Osteoporos Int 22: 859-71 (doi: 10.1007/s00198-010-1407-y).
54. Struthers A, Lang C (2007) The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage. Eur Heart J 28: 1678-82 (doi: 10.1093/eurheartj/ehm234).
55. van Deursen VM, Damman K, Voors AA, van der Wal MH, Jaarsma T, van Veldhuisen DJ, Hillege HL (2013) Prognostic value of plasma NGAL for mortality in heart failure patients. Circ Heart Fail 7(1): 35-42 (doi: 10.1161/CIRCHEARTFAILURE.113.000242).
56. Villacorta H, Ferradaes PDV, Mesquita ET, Nóbrega AC (2012) Microalbuminúria é um marcador prognóstico independente em pacientes com insuficiência cardíaca crônica. Arq Bras Cardiol 98: 62-9.
57. Witham MD, Crighton LJ, Gillespie ND, Struthers AD, Mcmurdo ME (2010) The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: A randomized controlled trial. Circ Heart Fail 3: 195-201 (doi: 10.1161/CIRCHEARTFAILURE.109.907899).